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J. Ghosh, D. Murray, N. Khwaja, M.O. Murphy and M.G. Walker*Department of Vascular Surgery, Manchester Royal Infirmary, Manchester, UKObjectives. Controversy exists regarding the optimal management of patients with coexisting coronary and extracranial
carotid artery disease. This study investigates the incidence of death, cerebrovascular events and myocardial infarction (MI)
in patients with asymptomatic significant carotid artery disease undergoing coronary artery bypass graft (CABG) surgery.
Design. Prospective cohort.
Methods. Fifty patients with asymptomatic carotid stenoses R70% associated with cervical bruits undergoing CABG
without prophylactic carotid endarterectomy (CEA) were followed up over a median period of 68 months following surgery
cerebrovascular events, MI and mortality were recorded. All patients received optimal secondary prevention for
cardiovascular disease unless contraindicated.
Results. No cerebrovascular events occurred within 30 days of surgery. One patient suffered an ipsilateral transient
ischaemic attack (TIA) 14 months after CABG. Two patients died within 30 days; one from an MI, the other from
pancreatitis. Three deaths occurred after 30 days; one from MI, one from primary lung cancer and one following rupture of
an abdominal aortic aneurysm. No non-fatal MIs occurred.
Conclusions. In this patient group the overall risk of death, cerebrovascular events and MI was 4% during the first 30 days
postoperatively and 8% thereafter. This compares favourably with published series for staged or combined CEA-CABG
procedures. For asymptomatic significant carotid disease, prophylactic CEA prior to CABG does not appear to confer any
advantage over CABG alone.Keywords: Asymptomatic carotid disease; Coronary bypass; Stroke.Introduction
The optimal management of patients with coexisting
carotid and coronary artery disease remains contro-
versial. The potential for stroke following CABG
surgery has led many to advocate combined or staged
prophylactic CEA-CABG in all patients with signifi-
cant carotid stenoses, whether symptomatic or not. A
recent review1 has identified CEA-CABG procedures
to be associated with a 10–12% combined cardiovas-
cular risk of death, stroke and MI during the 30 day
perioperative period. However, the outcome for
individual subpopulations remains unclear and, in
particular, the combined cardiovascular risk for thoseing author. M.G. Walker, Department of Vascular
chester Royal Infirmary, Oxford Road, Manchester
K.
0088+ 03 $35.00/0 q 2004 Elsevier Ltd. All rights reserwith significant asymptomatic carotid stenoses is
unknown.
In our institution, performance of combined CEA-
CABG is reserved only for those with symptomatic
carotid stenoses R70%. This study aims to determine
the incidence of death, stroke and MI for patients with
significant asymptomatic carotid artery disease fol-
lowing CABG without prophylactic CEA, and report
the long-term outcome.Materials and Methods
Of 3820 patients undergoing CABG between January
1995 and December 2000, 50 with asymptomatic
unilateral or bilateral internal carotid artery stenosis
R70% were prospectively followed up over a medianEur J Vasc Endovasc Surg 29, 88–90 (2005)
doi:10.1016/j.ejvs.2004.07.011, available online at http://www.sciencedirect.com onved.
Table 2. Anatomic distribution of carotid artery disease
% Stenosis Unilateral disease Bilateral disease
70–79% 15 5
80–99% 5 20
OcclusionC70–79% – 5
Total 20 30
Asymptomatic Carotid Stenoses and Coronary Artery Bypass 89period of 68 months (range 1 day to 96 months). These
50 patients were referred for investigation of carotid
bruits detected prior to CABG. Duplex ultrasound of
the carotid arteries determined degree of stenosis from
velocity of blood flow through the diseased region.
Those undergoing CABG combined with a second
cardiovascular procedure or with a previous history of
heart valve surgery were excluded.
Patient concurrent morbidity are summarised in
Table 1 and the anatomical distribution of carotid
disease in Table 2. Six patients had evidence of carotid
plaque ulceration. Three cases were emergent and one
was a redo procedure. Twenty-three CABGs were
performed using cardiopulmonary bypass (CPB) and
the others off-pump. Median cross clamp time was
63.0 min (range 28–86) and CPB time 96.7 min (range
71–147). Postoperatively 46 patients received aspirin,
33 statins and 3 anticoagulation.
All were followed up in outpatient clinics. Medical
records, correspondences, telephone communications
and death certificates were systematically assimilated
and all postoperative MIs, cerebrovascular events and
deaths recorded.Results
Whilst there was no intraoperative mortality, two
patients died during the 30-day perioperative period:
one from an MI at day 1 and the other from
pancreatitis at day 4. No cerebrovascular events or
non-fatal MIs occurred within this period. Following
the perioperative period 3 deaths occurred: one
following rupture of an abdominal aortic aneurysm
at 24 months, one from MI at 26 months and the third
from metastatic lung cancer at 92 months. After 14
months a 65-year-old female patient had a TIA
ipsilateral to a 75% stenosis.Table 1. Patient demographic data and concurrent morbidity
n
Male:female 32:18
Median age (range) 65.3 (51–68)
NYHA grade:
2 7 (14%)
3 38 (76%)
4 5 (10%)
Myocardial infarction 20
Diabetes mellitus 14
Hypertension 20
Hyperlipidaemia 33
Smoking 45
Atrial fibrillation 5Discussion
Stroke is a devastating complication of myocardial
revascularisation, having an incidence of 1.71%.2
Almost two thirds of strokes occur between 1 and 7
days postoperatively and are associated with advan-
cing age, cervical bruit, concurrent peripheral arterio-
pathy, re-do procedures, valve surgery, carotid
stenosis O50% and previous stroke. Whereas the
benefits of isolated CEA for symptomatic significant
carotid disease are well described, the preferred
management of concurrent coronary and carotid
artery disease remains contentious. This is largely
due to uncertainty regarding the outcome of patients
with significant asymptomatic carotid disease follow-
ing CABG without prophylactic CEA. A review by
Naylor determined the combined risk of mortality and
cardiovascular morbidity from stroke or MI, for
staged/combined CEA-CABG to be 10–12%.1 A
meta-analysis by Das observed the combined risk of
death and stroke to be 11.5% for isolated CABG in the
presence of O50% asymptomatic carotid stenoses,
although incidence of non-fatal MI was undeter-
mined.3 Brener found a 3-fold increase in postopera-
tive mortality, 13% versus 4%, in patients with
asymptomatic carotid disease.4 However, prophylactic
CEA-CABG appeared to confer no benefit with regard
to prevention of neurological complications.
This study observed no strokes or TIAs in the
immediate postoperative period and a combined
cardiovascular risk of MI, cerebrovascular events or
death of 4% during the first 30 days. The subsequent
incidence of MI, cerebrovascular events and death was
8%. These findings compare favourably with pub-
lished meta-analyses of cardiovascular complications
following combined/staged CEA-CABG procedures.
Furthermore, a concurrent audit of all patients in our
institution undergoing CABG alone showed an overall
30-day incidence of mortality and cerebrovascular
events of 4.2%.
The study cohort represented 1.3% of all patients
undergoing CABG at that time since carotid duplex
scanning was not routinely employed. It is acknowl-
edged that presence of carotid bruit, present in
approximately 6% of patients undergoing CABG, isEur J Vasc Endovasc Surg Vol 29, January 2005
J. Ghosh et al.90an unreliable predictor of carotid disease with as few
as 20% of bruits overlying a stenosis O50%.
Proponents of combined/staged CEA-CABG pro-
cedures in the presence of significant asymptomatic
carotid disease find justification from studies demon-
strating favourable mortality and morbidity.5
Additionally, the Asymptomatic Carotid Atherosclero-
sis Study (ACAS) is often quoted as a rationale for
prophylactic CEA.6 ACAS concluded that perform-
ance of CEA for asymptomatic carotid stenosisR60%
produced a projected 53% relative risk reduction in
ipsilateral stroke over 5 years. However, a subsequent
meta-analysis of five trials, including ACAS, deter-
mined that the absolute benefit of CEA for asympto-
matic disease in terms of stroke and mortality
reduction was minimal.7
The difficulty with unselected CEA combined with
CABG lies with the mounting body of evidence that
embolism originating from the aortic arch is the major
independent risk factor of post-CABG stroke.2,8,9
Given that the prevalence of preexisting atherosclero-
sis of the carotid arteries and ascending aorta of CABG
patients has been described as 14.3 and 30.2%,
respectively,10 it is unlikely that CEA is sufficient
prophylaxis for all strokes. It is thus timely to
reconsider the management of asymptomatic carotid
stenoses in patients requiring CABG. Carotid athero-
sclerosis is undeniably a risk factor for future
cerebrovascular events. Substantial level 1 evidence
has demonstrated the efficacy of medical primary and
secondary prevention of stroke. Asymptomatic sig-
nificant disease requires aggressive medical manage-
ment of concurrent morbidity and close monitoring for
appearance of symptoms. Symptomatic carotid dis-
ease necessitates definitive intervention in addition to
myocardial revascularisation. This study suggests thatEur J Vasc Endovasc Surg Vol 29, January 2005prophylactic CEA does not appear to confer an
advantage over CABG alone for patients with asymp-
tomatic significant carotid disease.References
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